The National Comprehensive Cancer Network (NCCN) has released Acute Lymphoblastic Leukemia, Version 2.2026, providing an updated framework for the management of acute lymphoblastic leukemia (ALL). One of the most notable developments is the increasingly established role of CD19-directed CAR-T cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
In the latest guideline, tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel are all incorporated into the treatment framework for relapsed/refractory B-ALL.
The positioning of CAR-T can be summarized as follows:
- Ph-negative relapsed/refractory B-ALL: CAR-T cell therapy has reached the Preferred treatment category and is now one of the core treatment options.
- Ph-positive relapsed/refractory B-ALL: CAR-T is listed under Other Recommended Regimens, with specific requirements related to prior tyrosine kinase inhibitor (TKI) therapy.
- Newly diagnosed B-ALL: CAR-T is not currently recommended as routine frontline consolidation. However, emerging evidence suggests that CAR-T may have a role in patients with measurable residual disease (MRD) after initial therapy.
- CAR-T followed by allogeneic hematopoietic cell transplantation (allo-HCT): The optimal role of transplant after CAR-T remains unclear.
The updated guideline therefore reflects an important shift: CAR-T is no longer simply an experimental option for heavily pretreated B-ALL. In appropriate patients with relapsed or refractory disease, it has become part of the NCCN’s preferred treatment strategy.
CAR-T Becomes a Preferred Option in Ph-Negative R/R B-ALL
For patients with relapsed or refractory Ph-negative B-ALL, NCCN lists all three CD19 CAR-T products as Preferred options with Category 2A recommendations:
| CAR-T therapy | NCCN position | Category |
|---|---|---|
| Tisagenlecleucel | Preferred | 2A* |
| Brexucabtagene autoleucel | Preferred | 2A |
| Obecabtagene autoleucel | Preferred | 2A |
*Unless otherwise specified, NCCN recommendations are Category 2A.
The guideline defines Category 2A as an intervention supported by lower-level evidence for which there is uniform NCCN expert-panel consensus that the intervention is appropriate, with at least 85% panel support.
Tisagenlecleucel is specifically indicated in the guideline for patients younger than 26 years with refractory disease or disease that has relapsed at least twice. Brexucabtagene autoleucel and obecabtagene autoleucel do not carry the same age or relapse-number qualification in this particular treatment table.
CAR-T therefore sits alongside other established options such as blinatumomab-based therapy and inotuzumab ozogamicin, although the exact treatment choice depends on disease characteristics, previous treatment, age, fitness, MRD status, and transplant history.
Ph-Positive R/R B-ALL: CAR-T Remains Recommended, but With More Specific Conditions
The picture is somewhat different for Ph-positive relapsed/refractory B-ALL.
Here, CAR-T is classified as Other Recommended, rather than Preferred. It is listed alongside TKI-based approaches, blinatumomab ± TKI, and inotuzumab ozogamicin ± TKI.
The guideline places specific conditions on CAR-T use:
- Tisagenlecleucel: patients younger than 26 years, with refractory disease or at least two relapses, and prior treatment with two TKIs.
- Brexucabtagene autoleucel: prior treatment must include a TKI.
- Obecabtagene autoleucel: prior treatment must include a TKI.
This distinction highlights the continuing importance of targeted therapy in Ph-positive B-ALL, where BCR::ABL1-directed treatment remains a central component of disease management.
Three Key CAR-T Studies Support the Updated NCCN Position
The NCCN guideline summarizes clinical evidence from major studies involving the three CAR-T products. Importantly, these studies enrolled different patient populations and used different designs, so their efficacy results should not be interpreted as direct head-to-head comparisons.
1. Tisagenlecleucel: ELIANA Established the Foundation in Children and Young Adults
The ELIANA study established some of the earliest pivotal evidence for CD19 CAR-T therapy in pediatric and young adult R/R B-ALL.
Among 75 children and young adults treated with tisagenlecleucel, the overall remission rate within three months was 81%, and all responding patients were MRD-negative.
Real-world CIBMTR registry data subsequently provided additional support, showing:
- Morphologic CR rate: 85%
- MRD negativity among patients achieving CR with available MRD assessment: 99%
- Durable remission at 12 months: 61% in the CIBMTR cohort versus 67% in ELIANA
An updated ELIANA analysis with a median follow-up of 24 months reported a 62% probability of relapse-free survival at 24 months among responders. Median duration of response and median overall survival had not been reached.
Notably, only 9% of patients who achieved CR subsequently underwent allo-HCT.
These findings have been particularly influential in the discussion surrounding whether some children and young adults can achieve durable, potentially curative disease control after CAR-T without routine consolidative transplantation.
2. Brexucabtagene Autoleucel: ZUMA-3 Extended CAR-T to Adults
For adults with R/R B-ALL, the ZUMA-3 study provided pivotal evidence supporting brexucabtagene autoleucel.
The phase 2 portion evaluated 71 enrolled patients, with 55 patients included in the treated efficacy population. The reported outcomes included:
- CR/CRi rate: 71%
- MRD-negative CR rate: 76%
- Median duration of response: 12.8 months
- Median relapse-free survival: 11.6 months
- Median overall survival: 18.2 months
The study also demonstrated that responses were frequently associated with deep molecular remission. Among the treated population, the most common grade ≥3 adverse events included anemia (49%) and pyrexia (36%).
These results established brexucabtagene autoleucel as an important CAR-T option for adults with relapsed/refractory B-ALL.
3. Obecabtagene Autoleucel: FELIX Adds Another Adult CAR-T Option
The FELIX study further expanded the adult B-ALL CAR-T landscape with obecabtagene autoleucel.
Among 127 patients who received at least one infusion, the study reported:
- Overall remission rate: 78%
- CR rate among patients with morphologic disease: 55%
- Median EFS: 11.9 months
- Median OS: 15.6 months
- Grade ≥3 CRS: 2.4%
- Grade ≥3 ICANS: 7.1%
The relatively low rates of severe CRS and ICANS were notable features of the FELIX study.
The study also suggested that disease burden before lymphodepletion matters. Patients with lower bone marrow blast counts had better subsequent outcomes than patients with very high disease burden.
CAR-T Is Also Being Explored Earlier in the Treatment Course
Although NCCN’s established recommendations for CAR-T remain concentrated in relapsed/refractory B-ALL, the 2026 guideline also points toward an important area of future development: using CAR-T as consolidation for patients with MRD-positive disease.
The guideline notes that emerging evidence suggests CAR-T may potentially serve as a consolidation strategy for selected patients who remain MRD-positive after achieving remission.
Two studies cited by NCCN include:
- Lu W, Wei Y, Cao Y, et al. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Cancer Immunol Immunother. 2021.
- Yin Z, Lin Y, Liu D, et al. CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis. Cancer Rep. 2022.
However, the evidence is not yet sufficient for NCCN to recommend CAR-T as routine frontline consolidation. More prospective data are needed.
Does Every Patient Need a Transplant After CAR-T?
This remains one of the most important unanswered questions.
The NCCN guideline explicitly states that “The role of allogeneic HCT following cellular therapy is unclear.”
In other words, NCCN does not recommend a universal strategy of either transplanting every patient after CAR-T or avoiding transplant in every patient.
The decision may depend on factors including:
- Depth and duration of response
- MRD status
- Disease burden
- Previous allo-HCT
- CAR-T response and persistence
- Patient age and overall condition
- Risk of relapse
The ELIANA experience illustrates why the question remains open. Only 9% of patients who achieved CR underwent subsequent allo-HCT, while some patients maintained long-term remission without transplantation. NCCN notes that these results suggest tisagenlecleucel may have curative potential for a subset of children and young adults without consolidative allo-HCT.
At the same time, the guideline continues to recommend consolidative HCT in certain patients who achieve a second remission before HCT and have not previously undergone transplantation.
The current evidence therefore supports an individualized approach rather than a one-size-fits-all CAR-T-to-transplant strategy.
What Does “Preferred” Mean in the NCCN Guidelines?
The NCCN treatment categories are important because they do not simply mean “approved” versus “not approved.”
In general:
- Preferred: considered to have a favorable balance of efficacy, safety, evidence, and, when appropriate, affordability. These are options that should generally be prioritized when applicable.
- Other Recommended: remains an appropriate treatment option, but may have somewhat less mature evidence, different toxicity considerations, or other factors affecting its overall priority.
- Useful in Certain Circumstances: appropriate for a specifically defined patient population or clinical situation.
Importantly, NCCN states that all recommendations are considered appropriate.
What the 2026 NCCN Update Means for B-ALL
The Version 2.2026 guideline reflects a broader evolution in B-ALL treatment.
CAR-T cell therapy has moved from being primarily associated with highly specialized clinical trials to becoming an established treatment option for relapsed/refractory B-ALL. For Ph-negative R/R B-ALL, three CD19 CAR-T therapies now occupy the Preferred category.
At the same time, the guideline remains cautious about expanding CAR-T into earlier lines of treatment and about automatically following CAR-T with allo-HCT.
The message from NCCN is therefore not simply that “CAR-T should replace transplant.” Rather, the 2026 guideline recognizes CAR-T as a core component of modern B-ALL treatment, while acknowledging that the optimal sequencing of CAR-T, targeted therapy, immunotherapy, and transplantation is still evolving.
For patients with relapsed or refractory B-ALL, this development is particularly significant. The expanding evidence base suggests that CAR-T can produce deep, MRD-negative remissions in patients who previously had limited treatment options, while ongoing research is now asking an even more important question: Can CAR-T be moved earlier in the treatment pathway and potentially reduce the need for subsequent transplantation in selected patients?
That question may shape the next generation of B-ALL treatment guidelines.
Source: National Comprehensive Cancer Network (NCCN), Acute Lymphoblastic Leukemia, Version 2.2026. Clinical trial data are summarized according to the cited evidence and should not be interpreted as direct cross-trial comparisons.
Rreference
NCCN Clinical Practice Guidelines in Oncology.Acute Lymphoblastic Leukemia. Version 2.2026. July 24, 2026.
